# Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

> **NCT03346434** · PHASE2,PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 202 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT03346434
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-30
- **Primary completion:** 2021-07-08
- **Final completion:** 2021-07-08
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2022-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03346434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03346434, "Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03346434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*